Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 15, 2022 16:05 ET
|
Biora Therapeutics, Inc.
Successfully completed PM-602 human study for its targeted therapeutics platform demonstrating promising device performance in active ulcerative colitis patients Successfully completed PM-611...
Biora Therapeutics Announces Successful Completion of Device Performance Study in Ulcerative Colitis Patients for its Targeted Therapeutics Platform
August 10, 2022 09:00 ET
|
Biora Therapeutics, Inc.
SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced topline results from its recently...
Biora Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update
August 08, 2022 09:00 ET
|
Biora Therapeutics, Inc.
SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced that it will report second quarter ended...
Biora Therapeutics Announces Five Abstracts Accepted at American College of Gastroenterology Annual Scientific Meeting 2022
August 03, 2022 09:00 ET
|
Biora Therapeutics, Inc.
SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced the acceptance of five abstracts for...
Biora Therapeutics to Participate in Upcoming BTIG Investment Conference
July 26, 2022 09:00 ET
|
Biora Therapeutics, Inc.
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced that the company’s management team will be...
Biora Therapeutics Shares Preclinical Data on Oral Delivery of Biologics at Controlled Release Society 2022
July 14, 2022 09:00 ET
|
Biora Therapeutics, Inc.
SAN DIEGO, July 14, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today shared two posters that were presented at the...
Biora Therapeutics Announces Successful Completion of Second Device Performance Study in Human Subjects for its Targeted Therapeutics Platform
July 07, 2022 09:00 ET
|
Biora Therapeutics, Inc.
SAN DIEGO, July 07, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced topline results from its recently...
Biora Therapeutics Announces Presentation at the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference
June 22, 2022 09:00 ET
|
Biora Therapeutics, Inc.
SAN DIEGO, June 22, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced the acceptance of an abstract presenting...
Biora Therapeutics Shares Presentation of Patient Data Establishing Correlation Between Drug Levels in Colon and Patient Outcomes in Ulcerative Colitis
May 31, 2022 09:00 ET
|
Biora Therapeutics, Inc.
SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today shared a presentation delivered during Digestive...
Biora Therapeutics Shares Data Presented at Digestive Disease Week 2022
May 25, 2022 09:00 ET
|
Biora Therapeutics, Inc.
Patient Data Suggests Multiple Additional Inflammatory Pathways, Supporting Potential Need for Combination Therapy for Ulcerative Colitis Patient Data Establishes Proof of Concept for Microbiome...